Table 3.
Deterministic cost-effectiveness results
| Olaparib plus bevacizumab | Bevacizumab | Increment | |
|---|---|---|---|
| Costs US$ | |||
| Drug acquisition and administration | 355,999 | 90,167 | 265,831 |
| Healthcare resource use | 12,144 | 4655 | 7490 |
| Subsequent treatment | 12,007 | 120,577 | −108,570 |
| Terminal care | 17,659 | 20,155 | −2496 |
| Adverse event | 4954 | 3000 | 1954 |
| Total | 402,763 | 238,554 | 164,209 |
| LYs | |||
| Progression-free | 8.80 | 4.00 | 4.80 |
| First progression | 0.27 | 1.12 | −0.84 |
| Second progression | 0.48 | 1.01 | −0.53 |
| Total | 9.55 | 6.12 | 3.43 |
| QALYs | |||
| Progression-free | 7.08 | 3.20 | 3.88 |
| First progression | 0.21 | 0.84 | −0.63 |
| Second progression | 0.32 | 0.68 | −0.36 |
| Total | 7.61 | 4.72 | 2.89 |
| ICER ($/LY) | 47,910 | ||
| ICER ($/QALY) | 56,863 | ||
ICER incremental cost-effectiveness ratio, LYs life-years, QALYs quality-adjusted life-years